Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06433752 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Study acronym: ENABLE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 109 to 111 Eligibility criteria expanded, about 5 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 5 words
  2. Trial sites expanded: 91 → 109 locationsv27
  3. Study sites: 90 to 91v26
  4. Study sites: 88 to 90v25
  5. Trial sites expanded: 85 → 88 locationsv24
  6. Primary and study completion pushed from Jul 1, 2027 to Apr 1, 2032 Enrollment increased: 500 → 2000 participantsv23 Show 1 more changeShow less
    • Enrollment increased: 500 → 2000 participants
  7. Trial sites expanded: 80 → 85 locationsv22
  8. Study sites: 78 to 80v21
  9. Re-verified, no change to tracked fieldsv20
  10. Study sites: 64 to 78v19
  11. Re-verified, no change to tracked fieldsv18
  12. Study sites: 62 to 64v17
  13. Re-verified, no change to tracked fieldsv16
  14. Study sites: 59 to 62v15
  15. Study sites: 58 to 59v14
  16. Re-verified, no change to tracked fieldsv13
  17. Study sites: 54 to 58v12
  18. Study sites: 48 to 54v11
  19. Study sites: 44 to 48v10
  20. Study sites: 39 to 44v9
  21. Study sites: 34 to 39v8
  22. Study sites: 29 to 34v7
  23. Study sites: 21 to 29v6
  24. Study sites: 18 to 21v5
  25. Study sites: 3 to 18v4
  26. Study sites: 1 to 3v3
  27. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jun 30, 2024 to Jul 22, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 30, 2024 to Jul 22, 2024
  28. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Trial Details
NCT Number NCT06433752
Lead Sponsor TG Therapeutics, Inc.
Conditions Relapsing Multiple Sclerosis, Multiple Sclerosis
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov